Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-203-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"el"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-203-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-204-0002
lpv:speaker	lp:Nikolaos Chountis2
lpv:spokenAs	member; Delegation for relations with Albania, Bosnia and Herzegovina, Serbia, Montenegro and Kosovo (2009-09-16--2014-06-30)3 member; ECON (2009-07-16--2012-01-18)3 unknown; Coalition of the Radical Left (2009-07-14--2014-06-30)3 substitute; AFET (2009-07-16--2012-01-18)3 member_of_the_bureau; EUL/NGL (2009-07-14--2014-06-30)3 member; Special Committee on the Financial, Economic and Social Crisis (2009-10-08--2011-07-31)3 substitute; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 substitute; SEDE (2009-07-16--2012-01-18)3
lpv:translated text	"The marketing of falsified medicinal products has increased public health risks over recent years. There are worrying data that, apart from the Internet, more and more falsified medicinal products are entering the legal supply chain. I voted in favour of the Matias report because: 1. It puts patient protection at the heart of the legislative proposal, by adopting measures to provide access to a high standard of safe and appropriate treatment and information. 2. It includes and regulates online sales of medicinal products, which were missing from the Commission proposal, despite the fact that over 50% of medicinal products purchased online are falsified. 3. It establishes safety features for prescription and non-prescription (black-listed) medicinal products, in the aim of preventing falsified medicinal products from entering the legal supply chain. 4. It demands full traceability of medicinal products and, at the same time, establishes an early warning system in all the Member States, so that medicinal products which are suspected of being dangerous can be withdrawn. 5. It sees falsification of medicinal products as an organised criminal activity and imposes strict penalties on the offenders. 6. Exports of medicinal products from the EU to third countries must satisfy the same safety criteria as those which apply to imports."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph